{"entity":{"id":"tubulis","kind":"company","name":"Tubulis (Gilead)","aka":[],"tldr":"German ADC company whose NaPi2b ADC TUB-040 posted a 59% response rate in platinum-resistant ovarian cancer; Gilead agreed to buy it for up to $5B.","summary":"Raised a record €344M Series C (October 2025) after TUB-040 phase 1/2a data at ESMO 2025 (59% ORR in platinum-resistant ovarian cancer; also lung adenocarcinoma). Gilead announced an acquisition at $3.15B upfront plus up to $1.85B milestones, expected to close Q2 2026. Proprietary Tubutecan and P5 conjugation chemistries.","asOf":"2026-09-04","links":[{"label":"Gilead acquisition","url":"https://www.biospace.com/business/gilead-swallows-another-partner-paying-up-to-5-b-for-adc-specialist-tubulis"}],"tags":[],"related":[],"cancers":["ovarian","nsclc"],"sections":["adcs"],"technologies":["adc","site-specific-conjugation"],"targets":[],"drugs":[],"companies":["gilead"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06657222","nct07736937","nct06303505"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Munich","country":"DE","companyType":"biotech","website":"https://tubulis.com","investors":[],"funding":[]},"route":"/companies/tubulis/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"site-specific-conjugation","kind":"technology","name":"Site-specific conjugation & linker chemistry","route":"/technologies/site-specific-conjugation/"}],"company":[{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","route":"/companies/gilead/"}],"trial":[{"id":"nct06303505","kind":"trial","name":"FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC","route":"/trials/nct06303505/"},{"id":"nct06657222","kind":"trial","name":"First in Human Study of TUB-030 in Patients With Advanced Solid Tumors","route":"/trials/nct06657222/"},{"id":"nct07736937","kind":"trial","name":"Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer","route":"/trials/nct07736937/"},{"id":"nct07806773","kind":"trial","name":"Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer","route":"/trials/nct07806773/"}]}}